• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Judge sanctions Boston Scientific lawyers in Nevro patent row

Judge sanctions Boston Scientific lawyers in Nevro patent row

May 9, 2018 By Brad Perriello

Boston Scientific NevroA federal judge in California yesterday sanction lawyers for Boston Scientific (NYSE:BSX) in a patent infringement battle with neurostimulation rival Nevro (NYSE:NVRO).

Back in October 2017, Judge Vince Chhabria of the U.S. District Court for Norther California found that, although the Nevro attorneys’ failure to correct a patent examiner’s misunderstanding of prior art was a little “sleazy,” it didn’t amount to inequitable conduct. In February, is was the turn of Boston’s attorneys when Chhabria chastised them for “frivolous and vexatious” conduct in filing motions to redact documents that could show that Boston Scientific intended to copy technology from Nevro and other competitors.

The judge denied Boston’s motion to reconsider his prior denial of the redaction bid because “Boston Scientific has again requested to seal information without a legitimate basis,” he wrote at the time, ordering the attorneys to show why they shouldn’t be sanctioned $500 apiece for filing the motions. In their responses, the five attorneys each disavowed any intent to mislead Chhabria or intentionally move to seal any documents without merit, with the lead attorneys apologizing for any offense taken by the judge.

Evidently unswayed, yesterday he made good on his threat and leveled $2,500 in sanction against the quintet, according to court documents.

“Nothing in any of the responses to the order to show cause comes close to justifying either the original sealing request or the motion for partial reconsideration. Nor, at the hearing on the order to show cause, was any legitimate justification offered for either the original sealing request or the motion for partial reconsideration. Both filings were objectively frivolous and therefore in clear violation of Rule 11 of the Federal Rules of Civil Procedure,” Chhabria wrote.

Although it’s true that the practice of corporate law comes with pressure from clients to keep information under seal without a legal reason, he wrote, “the answer is not to file frivolous sealing requests.”

“The answer is to firmly explain to their clients that litigation is a public process, and that the public has the right to know what the litigation is about, subject only to very limited exceptions. Mere embarrassment to a corporation is not one of those exceptions,” the judge wrote in fining each attorney $500.

“Next time, the sanction will be far heavier,” he warned.

The case dates back to November 2016, when Nevro filed a patent infringement suit against Boston Scientific claiming that infringement of patents relating to its Senza and HF10 spinal cord stimulation systems.

Filed Under: Legal News, Neuromodulation/Neurostimulation, Patent Infringement Tagged With: Boston Scientific, Nevro Corp.

More recent news

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy